AbbVie presents R&D pipeline update
ABBV•AbbVie added Phase 3 programs for ABBV-1480 in first-line NSCLC and etentamig combinations in multiple myeloma, and expects regulatory submissions for Rinvoq in two conditions in 2027. Etentamig monotherapy and Epkinly with R-CHOP are also anticipated to receive approval in 2027; ABBV-243’s Phase 1 inflammatory bowel disease program was discontinued.
1. Pipeline developments
AbbVie added Phase 3 programs for ABBV-1480 with chemotherapy in first-line non-small cell lung cancer and etentamig combinations in multiple myeloma. Etentamig monotherapy for third-line multiple myeloma has been submitted for regulatory review, with approval anticipated in 2027.
2. Expected submissions and readout
Rinvoq regulatory submissions for hidradenitis suppurativa and systemic lupus erythematosus are expected in 2027. Epkinly with R-CHOP in first-line diffuse large B-cell lymphoma completed its Phase 3 readout, with regulatory approval anticipated in 2027; AbbVie discontinued ABBV-243’s Phase 1 inflammatory bowel disease program.
